

4basebio PLC

("4basebio" or the "Company")

Director Dealing

Cambridge, UK, 4 April 2025 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, announces that it was informed by Dr. Heikki Lanckriet, CEO of the Company, that on 2 April 2025 he made the following purchases in ordinary shares in the capital of the Company through the market, on behalf of his three children.

Further details are set out in the Notification of Dealing Form below.

Director / PCA	Number of Ordinary Shares Acquired	Purchase Price (p)	Shareholding Following Acquisition	Shareholding Following Acquisition as a Percentage of Issued Share Capital
Heikki Lanckriet*	2,400	1,205	1,117,688	7.21%

*Refers to Heikki Lanckriet and persons closely associated with him.

The 2,400 additional shares purchased represent approximately 0.02 per cent. of the Company's issued share capital. The issued share capital of the Company comprises 15,496,393 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:

4basebio PLC +44 (0)1223 967 943

Dr. Heikki Lanckriet, CEO
Nominated Adviser +44 (0)20 7213 0880

Cairn Financial Advisers LLP

Jo Tuner / Sandy Jamieson / Ed Downes
Joint Broker +44 (0)20 7653 4000

RBC Capital Markets

Rupert Walford / Max Avison / Kathryn Deegan
Joint Broker +44 (0)20 7220 0500

Cavendish Capital Markets Limited

Geoff Nash / Nigel Birks

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company's objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.

Forward-looking statements

This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the persons discharging managerial responsibilities / person closely associated	
a)	Name Heikki Lanckriet	
2	Reason for the notification	
a)	Position/Status Chief Executive Officer	
b)	Initial notification/ Amendment Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name 4basebio plc	
b)	LEI 213800E2DX9EAIUNCB30	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument/identification Ordinary Shares ISIN: GB00BMCLYF79	

	code									
b)	Nature of the transaction	Acquisition of ordinary shares								
c)	Price(s) and volume(s)	<table border="1"><thead><tr><th>Date</th><th>Price(s)</th><th>Volume(s)</th><th></th></tr></thead><tbody><tr><td>02/04/2025</td><td>1,205p</td><td>2,400</td><td></td></tr></tbody></table>	Date	Price(s)	Volume(s)		02/04/2025	1,205p	2,400	
Date	Price(s)	Volume(s)								
02/04/2025	1,205p	2,400								
d)	Aggregated information- Aggregated volume- Price	2,4001,205p								
e)	Date of transaction	02 April 2025								
f)	Place of transaction	London Stock Exchange								
